Pharmacological targeting of peptidylarginine deiminase 4 prevents cancer-associated kidney injury in mice.

abstract：:Recently, the study of microRNAs has expanded our knowledge of the fundamental processes of cancer biology and the underlying mechanisms behind tumor metastasis. Extensive research in the fields of microRNA and its novel mechanisms of actions against various cancers has more recently led to the trial of a first cancer...

journal_title：Oncoimmunology

authors： Park JH,Theodoratou E,Calin GA,Shin JI

更新日期：2016-09-09 00:00:00

abstract：:Cleavage or shedding of the surface antigen, MHC class I chain-related (MIC) protein (A/B) has been known to be one of the mechanisms by which tumor cells escape host immune surveillance. Thus, any strategy to augment the surface expression of MICA/B could facilitate anticancer immune response. Here, we demonstrate th...

journal_title：Oncoimmunology

authors： Fu D,Geschwind JF,Karthikeyan S,Miller E,Kunjithapatham R,Wang Z,Ganapathy-Kanniappan S

更新日期：2015-01-14 00:00:00

abstract：:Graft-versus-host disease (GvHD) remains a significant impediment to allogeneic hematopoietic cell transplantation (HCT) success, necessitating studies focused on alleviating GvHD, while preserving the graft-versus-leukemia (GvL) effect. Based on our previous studies showing bendamustine with total body irradiation (B...

journal_title：Oncoimmunology

authors： Stokes J,Hoffman EA,Molina MS,Kummet N,Simpson RJ,Zeng Y,Katsanis E

更新日期：2020-04-30 00:00:00

abstract：:Innate immunity serves as a first line of defense against infectious agents, and germ-line-encoded pattern recognition receptors detect stressed and infected cells and elicit potent effector activities that accomplish efficient microbe containment. Recent evidence demonstrates that these pattern-sensing systems are al...

journal_title：Oncoimmunology

authors： Jinushi M

更新日期：2012-03-01 00:00:00

abstract：:Triple-negative breast cancer (TNBC) is characterized by broad genomic and transcriptional heterogeneity and results in a worse prognosis than other breast cancer types. Here, we integrated genomic and transcriptomic data combined with clinicopathologic information from 538 patients with TNBC and identified four novel...

journal_title：Oncoimmunology

authors： Chen H,Chong W,Yang X,Zhang Y,Sang S,Li X,Lu M

更新日期：2020-06-30 00:00:00

abstract：:Immunogenic cell death (ICD) induced by anticancer chemotherapeutics is usually preceded by premortem stress affecting the endoplasmic reticulum (ER). This ER stress does not reflect a canonical unfolded protein response (UPR) but rather manifests solely at the level of the phosphorylation of eIF2α. eIF2α phosphorylat...

journal_title：Oncoimmunology

authors： Bezu L,Sauvat A,Humeau J,Leduc M,Kepp O,Kroemer G

更新日期：2018-02-14 00:00:00

abstract：:In many cancers, regulatory T cells (Treg) play a crucial role in suppressing the effector immune response thereby permitting tumor development. Indeed, in mouse models, their depletion can promote the regression of tumors of various origins, including renal cell carcinoma when located subcutaneous (SC). In the presen...

journal_title：Oncoimmunology

authors： Devaud C,Westwood JA,Teng MW,John LB,Yong CS,Duong CP,Smyth MJ,Darcy PK,Kershaw MH

更新日期：2014-12-21 00:00:00

abstract：:Radiotherapy is an important therapeutic option for the treatment of cancer. Growing evidence indicates that, besides inducing an irreversible DNA damage, radiotherapy promotes tumor-specific immune response, which significantly contribute to therapeutic efficacy. We postulate that radiotherapy activates tumor-associa...

journal_title：Oncoimmunology

authors： Gupta A,Sharma A,von Boehmer L,Surace L,Knuth A,van den Broek M

更新日期：2012-12-01 00:00:00

abstract：:The immune system avoids oncogenesis and slows down tumor progression through a mechanism called immunosurveillance. Nevertheless, some malignant cells manage to escape from immune control and form clinically detectable tumors. Tetraploidy, which consists in the intrinsically unstable duplication of the genome, is con...

journal_title：Oncoimmunology

authors： Aranda F,Chaba K,Bloy N,Garcia P,Bordenave C,Martins I,Stoll G,Tesniere A,Kroemer G,Senovilla L

更新日期：2018-05-21 00:00:00

abstract：:Despite the clinical success of anti-PD1 antibody (α-PD1) therapy, the immune mechanisms contributing to the antineoplastic response remain unclear. Here, we describe novel aspects of the immune response involved in α-PD1-induced antitumor effects using an orthotopic Kras (G12D)/p53(R172H)/Pdx1-Cre (KPC) model of panc...

journal_title：Oncoimmunology

authors： D'Alincourt Salazar M,Manuel ER,Tsai W,D'Apuzzo M,Goldstein L,Blazar BR,Diamond DJ

更新日期：2016-03-16 00:00:00

abstract：:A missense mutation in RHOA encoding p.Gly17 Val has been reported to occur frequently in angioimmunoblastic T-cell lymphoma (AITL). Here, we describe a murine model which expresses the human RHOA mutant gene product in a T-cell specific manner and develops AITL-like symptoms. Most transgenic mice feature with latency...

journal_title：Oncoimmunology

authors： Lee GJ,Jun Y,Yoo HY,Jeon YK,Lee D,Lee S,Kim J

更新日期：2020-05-13 00:00:00

abstract：:We have recently described two types of Langerhans cells (LCs), which develop via separate pathways in steady-state conditions and during inflammation. Here, we propose that these two types of LCs differ in their requirement for transforming growth factor β1 (TGFβ1), and we discuss how TGFβ1 impacts on the development...

journal_title：Oncoimmunology

authors： Seré K,Felker P,Hieronymus T,Zenke M

更新日期：2013-03-01 00:00:00

abstract：:Tumor-associated macrophages (TAM) are well known as a key player in the tumor microenvironment, which support cancer progression. More recently, a lineage of monocytes characterized by the expression of the TIE-2/Tek angiopoietin receptor identified a subset of circulating and tumor-associated monocytes endowed with ...

journal_title：Oncoimmunology

authors： Turrini R,Pabois A,Xenarios I,Coukos G,Delaloye JF,Doucey MA

更新日期：2017-03-16 00:00:00

abstract：:Tumor-associated macrophages play a central role in tumor progression and metastasis. Macrophages can also promote the resistance of malignant cells to chemotherapy by stimulating the upregulation of cytidine deaminase, an intracellular enzyme that catabolizes the active form of gemcitabine. Targeting macrophage-depen...

journal_title：Oncoimmunology

authors： Amit M,Gil Z

更新日期：2013-12-01 00:00:00

abstract：:Macrophages promote the growth of leiomyosarcoma (LMS), a malignant soft-tissue tumor. CD47 on tumor cells binds to the macrophagic receptor signal regulatory protein α (SIRPα) and prevents phagocytosis. We showed that anti-CD47 monoclonal antibodies (mAbs) allow macrophages to engulf LMS cells and prevent tumor growt...

journal_title：Oncoimmunology

authors： Edris B,Weiskopf K,Weissman IL,van de Rijn M

更新日期：2012-10-01 00:00:00

abstract：:Co-stimulatory signals induced by ligands of the tumor necrosis factor superfamily (TNFSF) play a central role in T cell activation and have emerged as a promising strategy in cancer immunotherapy. Here, we established a novel class of bifunctional co-stimulatory fusion proteins with the aim to boost T cell activation...

journal_title：Oncoimmunology

authors： Fellermeier-Kopf S,Gieseke F,Sahin U,Müller D,Pfizenmaier K,Kontermann RE

更新日期：2018-08-01 00:00:00

abstract：:The engineering of T lymphocytes to express chimeric antigen receptors (CARs) aims to establish T cell-mediated tumor immunity rapidly. In this study, we conducted a pilot clinical trial of autologous or donor- derived T cells genetically modified to express a CAR targeting the B-cell antigen CD19 harboring 4-1BB and ...

journal_title：Oncoimmunology

authors： Dai H,Zhang W,Li X,Han Q,Guo Y,Zhang Y,Wang Y,Wang C,Shi F,Zhang Y,Chen M,Feng K,Wang Q,Zhu H,Fu X,Li S,Han W

更新日期：2015-05-26 00:00:00

abstract：:Natural killer (NK) cells are integral components of the antitumor immune response. The downregulation of ligands for NK-cell stimulatory receptors represents a strategy whereby glioblastoma cells can evade NK-cell attacks. Histone deacetylase inhibitors can stimulate the (re)expression of these ligands, driving cytot...

journal_title：Oncoimmunology

authors： Adamopoulou E,Naumann U

更新日期：2013-08-01 00:00:00

abstract：:Immunotherapies targeting programmed cell death protein 1 (PD-1) or its ligand, programmed cell death ligand 1 (PD-L1), dramatically improve the survival of melanoma patients. However, only ∼40% of treated patients demonstrate a clinical response to single-agent anti-PD-1 therapy. An intact tumor response to type-II i...

journal_title：Oncoimmunology

authors： Luo N,Formisano L,Gonzalez-Ericsson PI,Sanchez V,Dean PT,Opalenik SR,Sanders ME,Cook RS,Arteaga CL,Johnson DB,Balko JM

更新日期：2018-03-06 00:00:00

abstract：:The immune microenvironment in follicular lymphoma (FL) plays an important role in controlling disease characteristics. To characterize the T-cell receptor (TCR) repertoire in follicular lymphoma (FL) tissues, we applied a next-generation sequencing platform and deeply sequenced TCR cDNAs of T-cell subset populations ...

journal_title：Oncoimmunology

authors： Liu X,Venkataraman G,Lin J,Kiyotani K,Smith S,Montoya M,Nakamura Y,Kline J

更新日期：2015-02-03 00:00:00

abstract：:The elicitation of efficient antitumor immune responses requires the optimal activation of tumor-associated dendritic cells (DCs). Our comparison of the effect of various immunostimulatory treatments on DCs revealed that the best predictor of the success of immunotherapy is not the activation of existing DC population...

journal_title：Oncoimmunology

authors： Kuhn S,Ronchese F

更新日期：2013-11-01 00:00:00

abstract：:Targeting antigens directly to dendritic cells (DCs) in situ has emerged as a promising strategy to potentiate immunity. A recent clinical trial of antibody-mediated targeting of tumor antigen NY-ESO1 to the DC receptor DEC-205 demonstrated an induction of strong cellular and humoral responses. Recent studies with DC-...

journal_title：Oncoimmunology

authors： Dhodapkar MV,Dhodapkar KM

更新日期：2014-08-03 00:00:00

abstract：:Colorectal cancer (CRC) infiltration by cells expressing myeloperoxidase (MPO) or CD8 positive T lymphocytes has been shown to be independently associated with favorable prognosis. We explored the relationship occurring between CD8+ and MPO+ cell CRC infiltration, its impact on clinical-pathological features and its p...

journal_title：Oncoimmunology

authors： Däster S,Eppenberger-Castori S,Hirt C,Soysal SD,Delko T,Nebiker CA,Weixler B,Amicarella F,Iezzi G,Governa V,Padovan E,Mele V,Sconocchia G,Heberer M,Terracciano L,Kettelhack C,Oertli D,Spagnoli GC,von Holzen U,Tornil

更新日期：2015-05-29 00:00:00

abstract：:Immune tolerance induced by regulatory mechanisms is an integral and fundamental part of immunity. In therapeutic settings, however, tolerance may significantly limit efficacy. Here, we summarize possible strategies to enhance therapeutic antibody dependent cellular cytotoxicity by overcoming NK cell tolerance. ...

journal_title：Oncoimmunology

authors： Terszowski G,Klein C,Schmied L,Stern M

更新日期：2015-04-02 00:00:00

abstract：:The inspection of the mechanisms through which autophagy modulates immunogenic cell death revealed that the autophagic response of cancer cells to reactive oxygen species-dependent endoplasmic reticulum stress suppresses the exposure of calreticulin on the cell surface, the phenotypic maturation of dendritic cells (DC...

journal_title：Oncoimmunology

authors： Garg AD,Dudek AM,Agostinis P

更新日期：2013-10-01 00:00:00

abstract：:The alarmin IL-33 is an IL-1 family member that stimulates pleiotropic immune reactions depending on the target tissue and microenvironmental factors. In this study, we have investigated the role of IL-33/ST2 axis in antitumor response to melanoma. Injection of IL-33 in mice-bearing subcutaneous B16.F10 melanoma resul...

journal_title：Oncoimmunology

authors： Lucarini V,Ziccheddu G,Macchia I,La Sorsa V,Peschiaroli F,Buccione C,Sistigu A,Sanchez M,Andreone S,D'Urso MT,Spada M,Macchia D,Afferni C,Mattei F,Schiavoni G

更新日期：2017-04-20 00:00:00

abstract：:We have recently reported that the PD-1 and CTLA4 signaling pathways are active in both effector and regulatory T cells, causing profound immune dysfunctions in the tumor microenvironment. In line with this notion, the dual blockade of PD-1- and CTLA4-conveyed signals may exert robust therapeutic effects. Here, we dis...

journal_title：Oncoimmunology

authors： Duraiswamy J,Freeman G,Coukos G

更新日期：2013-10-01 00:00:00

abstract：:The advent of immune checkpoint blockade as a new strategy for immunotherapy has changed the outlook for many aggressive cancers. Although complete tumor eradication is attainable in some cases, durable clinical responses are observed only in a small fraction of patients, underlining urgent need for improvement. We pr...

journal_title：Oncoimmunology

authors： Ekiz HA,Lai SA,Gundlapalli H,Haroun F,Williams MA,Welm AL

更新日期：2018-07-11 00:00:00

abstract：:Breast cancer spread to distant sites is often incurable. Our recent findings demonstrate that Type I interferons secreted by tumor cells induce anti-metastatic immune responses that prevent breast cancer metastasis to the bone. This provides novel insights into the importance of the crosstalk between neoplastic and i...

journal_title：Oncoimmunology

authors： Slaney CY,Möller A,Hertzog PJ,Parker BS

更新日期：2013-01-01 00:00:00

abstract：:Epithelial Ovarian cancer (EOC) is the most lethal gynecological malignancy and has limited curative therapeutic options. Immunotherapy for EOC is promising, but clinical efficacy remains restricted to a small percentage of patients. Several lines of evidence suggest that the low response rate might be improved by com...

journal_title：Oncoimmunology

authors： Brunekreeft KL,Paijens ST,Wouters MCA,Komdeur FL,Eggink FA,Lubbers JM,Workel HH,Van Der Slikke EC,Pröpper NEJ,Leffers N,Adam J,Pijper H,Plat A,Kol A,Nijman HW,De Bruyn M

更新日期：2020-05-13 00:00:00